Intelligent Bio Solutions Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Intelligent Bio Solutions (NASDAQ:INBS) Second Quarter 2024 Results
Key Financial Results
Revenue: US$764.1k (up 114% from 2Q 2023).
Net loss: US$1.97m (loss widened by 368% from 2Q 2023).
US$2.07 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Intelligent Bio Solutions EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 24%. Earnings per share (EPS) exceeded analyst estimates by 36%.
Looking ahead, revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are up 14% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 6 warning signs for Intelligent Bio Solutions (of which 3 make us uncomfortable!) you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
